Natera said it is preparing to expand beyond minimal residual disease (MRD) and into early cancer detection as regulatory wins add indications for its Signatera liquid biopsy platform. Over the past four months, Natera highlighted approvals in the U.S. and Japan and certifications supporting broader Europe deployment. The company pointed to FDA approval for Signatera in muscle-invasive bladder cancer as a companion diagnostic, inclusion in NCCN guidelines for that indication, and Japan approval from PMDA for colorectal cancer. Natera also cited an In Vitro Diagnostic Regulation certification in Europe for Signatera’s multi-cancer use. Natera said colorectal will be the first indication for Signatera in Japan, with commercial launch expected toward the end of this year or early next year pending reimbursement clarifications. It also referenced an upcoming Japan readout—CIRCULATE-Japan (VEGA de-escalation)—expected in 2027. For MRD players, the update reflects how regulatory momentum is increasingly used as a lever to broaden both clinical scope and market reach.